generally at a low dose, to maintain control of asthma and allergy symptoms. The minimum effective dose should be prescribed to minimize glucocorticoid toxicity. Treatment of disease relapse Recommendation: For patients with EGPA who have experienced relapse with severe disease manifestations after prior successful remission induction with cyclophosphamide, we conditionally recommend treatment with rituximab over cyclophosphamide for remission re-induction. Rituximab is favored based on the